Journal List > Tuberc Respir Dis > v.61(2) > 1000975

TOOLS
Lee: Clinical Year Review of COPD
Review
Tuberculosis and Respiratory Diseases

Tuberculosis and Respiratory Diseases 2006; 61(2): 101-113.

Published online: 31 August 2006

DOI: https://doi.org/10.4046/trd.2006.61.2.101

Clinical Year Review of COPD

Kwan-Ho Lee, M.D.

Division of Pulmonary-Allergology, Department of Internal Medicine Yeungnam University College of Medicine, Daegu, Republic of Korea.

Address for correspondence: Kwan Ho Lee, M.D., Division of Pulmonary-Allergology, Department of Internal Medicine Yeungnam University College of Medicine, 317-1, Daemyeng-dong, Nam-gu, Daegu, 705-717, Republic of Korea. Phone: 82-53-620-3838, Fax: 82-53-393-6884, ghlee@med.yu.ac.kr

Copyright © 2006 The Korean Academy of Tuberculosis and Respiratory Diseases

Figures and Tables

Figure 1
Number of Papers of Respiratory Diseases from 2000 to 2005 years.
trd-61-101-g001
Figure 2
Comparison of nasal wash fluid IL-8 concentration in 35 patients with COPD and 12 control subjects of similar age, sex, and smoking status. Box plot represents median, IQR, and range (p=0.009).
trd-61-101-g002
Figure 3
Comparison of nasal bacterial load in 47 COPD patients with and without a lower airway colonizing PPM. Box plot represents median, IQR, and range (p=0.016).
trd-61-101-g003
Figure 4
Mean forced expiratory volume in one second (FEV1: adjusted for period, centre and patient within centre) before and during 24 h after the inhalation of tiotropium q.d. (●). Formoterol b.i.d. (◆), and tiotropium plus formoterol q.d. (■) at the end of the 6-week treatment periods.
trd-61-101-g004
Figure 5
Mean forced vital capacity (FVC: adjusted for period, centre and patient within centre) before and during 24 h after the inhalation of tiotropium q.d. (●). formoterol b.i.d. (◆), and tiotropium plus formoterol q.d. (■) at the end of the 6-week treatment periods.
trd-61-101-g005
Figure 6
Effect of early treatment on recovery of exacerbation symptoms. Patient mean total recovery time (days) plotted against the patient mean treatment delay (i.e., time from onset of exacerbation symptoms to initiation of therapy) (days) in 108 patients (regression coefficient 0.42 day/day delay; confidence interval, 0.19 to 0.65; p < 0.001).
trd-61-101-g006
Figure 7
The reported P values are for the entire study period based on a Cox proportional hazards regression stratified by center.
trd-61-101-g007
Figure 8
Kaplan-Meier estimates of the probability of remaining exacerbation-free. ------ : tiotropium, n=497; - - - - : placebo, n=506.
Time to first exacerbation: p<0.001 versus placebo (calculated using the log-rank test).
trd-61-101-g008
Figure 9
Mean change in trough FEV1 (ml/year) in the tiotropium and placebo groups from days 8 to 344 (A) and from days 50 to 344 (B).
trd-61-101-g009
Figure 10
An algorithm showing which patients with an acute exacerbation of chronic obstructive pulmonary disease (COPD) should receive antibiotic treatment.
trd-61-101-g010
Figure 11
Comparative ROC Type II curves and C statistics value for IC/TLC ratio, FEV1, and BODE Index as predictors of mortality in patients with COPD. The sensitivity and specificity of IC/TLC are greater than that of the FEV1 but less than that of the BODE Index.
trd-61-101-g011

References

1. Hurst JR, Wilkinson TM, Perera WR, Donaldson GC, Wedzicha JA. Relationships among bacteria, upper airway, lower airway, and systemic inflammation in COPD. Chest. 2005. 127:1219–1226.
2. Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006. 173:71–78.
3. Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, Hurst JR, et al. Airway and systemic inflammation and decline in lung function in patients With COPD. Chest. 2005. 128:1995–2004.
4. Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD. Chest. 2004. 126:926–934.
5. Wouters EF. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005. 2:26–33.
6. Buffels J, Degryse J, Heyrman J, Decramer M. Office spirometry significantly improves early detection of COPD in general practice. Chest. 2004. 125:1394–1399.
7. Dales RE, Vandemheen KL, Clinch J, Aaron SD. Spirometry in the primary care setting: influence on clinical diagnosis and management of airflow obstruction. Chest. 2005. 128:2443–2447.
8. Zielinski J, Bednarek M. Early detection in a high-risk population using spirometric screenig. Chest. 2001. 119:731–736.
9. Bolton CE, Ionescu AA, Edwards PH, Faulkner TA, Edwards SM, Shale DJ. Attaining a correct diagnosis of COPD in general practice. Respir Med. 2005. 99:493–500.
10. O'Donnell DE, Flűge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respoir J. 2004. 23:832–840.
11. Verkindre C, Bart F, Aguilaniu B, Fortin F, Guérin JC, le Merre C, et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration. 2006. 73:420–427.
12. Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba FC, Richter K, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest. 2005. 128:1168–1178.
13. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005. 26:214–222.
14. van Noord JA, Aumann JL, Janssens E, Vehaert J, Smeets JJ, Mueller A, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest. 2006. 129:509–517.
15. Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves outcomes of exacervations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004. 169:1298–1303.
16. Parker CM, Voduc N, Aaron SD, Webb KA, O'Donnell DE. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J. 2005. 26:420–428.
17. Stevenson NJ, Walker PP, Costello RW, Calverley PM. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005. 172:1510–1516.
18. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA Jr, Korducki L, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator. Ann Intern Med. 2005. 143:317–326.
19. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J. 2006. 27:547–555.
20. Celli BR. Chronic obstructive pulmonary disease from unjustified nihilism to evidence-based optimism. Proc Am Thorac Soc. 2006. 3:58–65.
21. Buist S. COPD: a common disease that is preventable and treatable. Prim Care Rsepir J. 2006. 15:7–9.
22. Anzueto A, Tashkin D, Menjoge S, Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther. 2005. 18:75–81.
23. Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. Eur Respir J. 2005. 25:1084–1106.
24. Wilson R. Treatment of COPD exacerbations: antibiotics. Eur Respir Rev. 2005. 14:32–38.
25. Beading C, Slifka MK. How do viral infections predispose patients to bacterial infections? Curr Opin Infect Dis. 2004. 17:185–191.
26. Wikinson TM, Hurst JR, Perera WR, Wilks M, Donaldson GC, Wedzicha JA. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest. 2006. 129:317–324.
27. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987. 106:196–204.
28. van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C, Hendrix R. Clinical predictors of bacterial involvement in exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis. 2004. 39:980–986.
29. Rosell A, Monsó E, Soler N, Torres F, Angrill J, Riise G, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med. 2005. 165:891–897.
30. Wilson R. Treatment of COPD exacerbations: antibiotics. Eur Respir Rev. 2005. 14:32–38.
31. Sethi S. Bacteria in exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004. 1:109–114.
32. Wilson R, Schentag JJ, Ball P, Mandell L. A comparison of gemifloxacin and clrithromycin in acute exacerbations of chronic bronchitis and lung-term clinical outcomes. Clin Ther. 2002. 24:639–652.
33. Wilson R, Allegra L, Huchon G, Izquierdo JL, Jones P, Schaberg T, et al. Short-term and long-term outcomes of moxifloxcin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest. 2004. 125:953–964.
34. Martinez FJ, Anzueto A. Appropriate outpatient treatment of acute bacterial exacerbation of chronic bronchitis. Am J Med. 2005. 118:Suppl 7A. 39S–44S.
35. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005. 171:591–597.
36. Celli BR, Cote CG, Marin J, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004. 350:1005–1012.
37. Ong KC, Earnest A, Lu SJ. A multidimensional grading system (BODE Index) as predictor of hospitalization for COPD. Chest. 2005. 128:3810–3816.
38. Cote CG, Celli BR. Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J. 2005. 26:630–636.
TOOLS
Similar articles